Published in final edited form as:
Cancer Res. 2010 November 1; 70(21): 8802–8811. doi:10.1158/0008-5472.CAN-10-0312.

Alternative Cyclin D1 Splice Forms Differentially Regulate the DNA Damage Response

Zhiping Li[1], **Xuanmao Jiao**[1], **Chenguang Wang**[1], **L. Andrew Shirley**[1], **Hany Elsaleh**[2], **Olav Dahl**[3], **Min Wang**[1], **Evi Soutoglou**[4], **Erik S. Knudsen**[1], and **Richard G. Pestell**[1,*]

[1] Departments of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107

[2] The Australian National University, ANU College of Medicine and Health Sciences, Radiation Oncology, The Canberra Hospital, PO Box 11, Woden ACT 2606, Australia

[3] Department of Oncology, Haukeland University Hospital, N-5021, Bergen, Norway

[4] Cancer Department, IGBMC. 1 Rue Laurent Fries, 67404, Illkirch, France

Abstract

The DNA damage response (DDR) activates downstream pathways including cell cycle checkpoints. The *cyclin D1* gene is overexpressed or amplified in many human cancers and is required for gastrointestinal, breast, and skin tumors in murine models. A common polymorphism in the human *cyclin D1* gene is alternatively spliced, resulting in cyclin D1a and D1b proteins that differ in their carboxyl terminus. Cyclin D1 overexpression enhances DNA-damage induced apoptosis. The role of cyclin D1 and the alternative splice form in regulating the DDR is not well understood. Herein cyclin D1a overexpression enhanced the DDR as characterized by induction of γH2AX phosphorylation, the assembly of DNA repair foci, and specific recruitment of DNA repair factors to chromatin, and G_2/M arrest. Cyclin D1 deletion in fibroblasts or siRNA mediated reduction of endogenous cyclin D1 in colon cancer cells reduced the 5-FU-mediated DDR. Mechanistic studies demonstrated cyclin D1a, like DNA repair factors, elicited the DDR when stably associated with chromatin.

INTRODUCTION

The ability to sense DNA damage is determined through activation of the serine/threonine kinase, ATM (ataxia-telangiectasia mutated), DNA-PK (DNA-dependent protein kinase) and ATR (ataxia-telangiectasia and Rad3 related) (1). Replication stress induces ATR activation while both ATM and ATR are induced in response to double-stranded DNA break repair. The rapid targeting of DNA repair factors near the site of damage gives rise to nuclear foci (2). The early DNA damage sensor complex involves MRN (MRE11/Rad50/NBS1), the transducer proteins MDC1 and 53BP1 and the phosphotidylinositol 3-kinase (PI-3-kinase) ATM/DNA-PK/ATR which phosphorylate H2AX and the Chk1/Chk2 cell cycle kinases (3). Phosphorylation of histone H2AX on serine residues of the carboxyl terminus (Ser139) (producing γH2AX) recruits proteins that sense or signal the presence of DNA damage, inducing the response that leads to DNA repair (4).

*Corresponding Author: Richard G. Pestell, The Kimmel Cancer Center, Department of Cancer Biology, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107, Tel: 215-503-5692; Fax: 215-503-9334 For Reprints: richard.pestell@jefferson.edu.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

The role of the DDR in tumorigenesis is complex. Defects of the MRN complex (MER11, Rad50, NBS1) occur at the preinvasive carcinoma *in situ* and γH2AX activation is commonly observed among familial breast tumors (5). Activated oncogenes are capable of inducing both double stranded DNA break (DSB) and a DDR in NIH3T3 cells. These oncogenes include *myc, ras, mos, cdc25A, E2F1,* and *cyclin E* (6–8). DNA damage is also a feature of pre-malignant tissue (9,10) suggesting oncogenic stress in non-malignant cells may contribute to tumorigenesis. Preferential activation of the DDR occurs in early, preinvasive lesions including ductal carcinoma *in situ* of the breast (9,10).

Activation of cell cycle control proteins is also an early feature of tumorigenesis. The cyclins encode essential components of the cell-cycle machinery, binding and activating their specific cyclin-dependent kinase partners (11). The abundance of cyclin D1 has been shown to play a role in cell-type dependent radiation-induced sensitivity. *Cyclin D1*$^{-/-}$ MEFs have enhanced apoptosis evoked by γ irradiation (12) and cyclin D1 expression also inhibited UV induced apoptosis in the presence of p300 (13). In contrast breast cancer cell lines overexpressing cyclin D1 showed enhanced apoptosis in response to γ irradiation (14,15) suggesting cell type specific differences governing cyclin D1 mediated apoptosis. The abundance of cyclin D1 mediates a G_1 cell-cycle arrest, as interference with cyclin D1 degradation prevents G_1 arrest in cell exposed to γ irradiation induced DNA damage (12) and G_2/M arrest (16). Collectively these studies suggest overexpression of cyclin D1 enhances γ irradiation induced apoptosis, however the role of endogenous cyclin D1 and the molecular mechanisms by which cyclin D1 may mediate the DNA damage response is not well understood.

The cyclin D1 gene encodes the regulatory subunit of a holoenzyme that phosphorylates the pRb protein. In addition, cyclin D1 promotes cell migration, regulates cellular metabolism, conveys transcriptional functions and is recruited to DNA in the context of local chromatin (17). The human *cyclin D1* gene is polymorphic (reviewed in (18)). The polymorphism (A870G), located at the splice donor region at the exon 4-intron 4 boundary, modulates the efficiency of alternate splicing between exon 4 and 5. As a result of the altered splicing that occurs, the coding region downstream is altered such that the amino acid sequence of the C terminus of cyclin D1 is altered (18). Thus, two isoforms of cyclin D1 are produced, the canonical isoform termed cyclin D1a and the alternately spliced isoform termed cyclin D1b. These proteins are distinct in their C termini. Clinical studies have associated this polymorphism with an increased risk of colon and rectal cancer, early onset squamous cell carcinoma, head and neck cancer, and transitional cell carcinoma of the bladder (18,19). Both isoforms encode regulatory subunits that can stimulate CDK4/6 activity; however, cyclin D1b has a reduced capacity to phosphorylate pRb and advance cell cycle progression (20). The role of cyclin D1a vs the cyclin D1b isoform in the DNA damage response has not previously been examined. It may be important in understanding the differences in transforming capacity of the two isoforms (20) and/or targeting therapy for cancer patients.

The current studies were conducted to determine whether cyclin D1 isoforms may affect the DDR signal pathway. SiRNA to endogenous cyclin D1 and isoform specific reconstitution overexpression experiments in *cyclin D1*$^{-/-}$ MEFs/3T3s allowed the identification of an isoform specific DDR. Recent studies have indicated the physical tethering of these DNA repair factors to chromatin is sufficient to induce the DDR signaling cascade (21). The current studies demonstrated that cyclin D1a, but not cyclin D1b, recruitment to chromatin was sufficient to elicit the DDR.

MATERIALS AND METHODS

Plasmids

Cyclin D1a and cyclin D1b was amplified by PCR from MSCV-cyclin D1a-IRES-GFP and MSCV-cyclin D1b-IRES-GFP (22) and cloned at the C-terminus of the Cherry-lacR-NLS vector (21) in *KpnI*/*XmaI* sites. Primers were used as the following: Cyclin D1 forward: cggggtaccgaacaccagctcctgtgct; Cyclin D1a reverse: tccccccgggtcagatgtccacgtcccgca; Cyclin D1b reverse: tccccccgggtcacccttgggggccttg. All plasmid DNA constructs were verified by sequencing.

Cell Culture, Treatment, and Transfection

Cyclin D1$^{+/+}$ and *cyclin D1*$^{-/-}$ primary mouse embryonic fibroblasts (MEFs) and 3T3 cells cultures, retroviral infected *cyclin D1*$^{-/-}$ MEFs and 3T3 cells were prepared as described previously (22–24). *p21*$^{Cip1+/+}$ and *p21*$^{Cip1-/-}$ MEFs were obtained from Dr. Philip Leder (Harvard Medical School, Boston, MA) and Dr. Dale S. Haines (Temple University School of Medicine, Philadelphia, PA). All MEFs, 3T3s, human kidney 293T cells, MCF-7 human breast cancer cells and HCT116 human colon cancer cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing penicillin and streptomycin (100 mg of each/liter) and supplemented with 10% FBS. The NIH 2/4 stable cell line that contains 256 repeats of the lac operator sequence (lacO) stably integrated on chromosome 3 (25) was maintained in DMEM with 10% FBS and 400 μg/ml hygromycin (Invitrogen). The NIH2/4 stable cell line was transfected using the Nucleofector kit for immortalized cell lines (Amaxa, Nucleofector R) as described previously (21). For the analysis of cyclin D1-mediated responses after DNA damage, MEFs or 3T3 cells were treated with ionizing radiation (IR) at the indicated dosage and times after treatment or doxorubicin (Sigma) at the indicated dosage and period of time of treatment.

Immunofluorescence

Immunoflurescence was conducted as described previously (22).

Immunoprecipitation and Western Blotting

Immunoprecipitation and Western Blotting were conducted as described previously (22).

Neutral pH Comet Assay

Neutral pH comet assays were conducted using the CometAssay Kit (Trevigen). After treatment with Doxorubicin or control, cells were harvested and mixed with low-melting temperature agarose. After lysis, electrophoresis was conducted at 1V/cm for 20 minutes. Slides were stained with SYBG green dye for 10 min and visualized on a Zeiss LSM 510 META Confocal Microscope with a 20× objective. The relative length and intensity of SYBG green-stained DNA tails to heads was proportional to the amount of DNA damage present in the individual nuclei and was measured by Olive tail moment using TriTek Comet Score software (TriTek) (26).

Additional materials and methods are discussed in Supplemental Information.

RESULTS

Endogenous cyclin D1 mediates the DNA damage response (DDR)

A surrogate assay for the measurement of double stranded DNA breaks in the cell is the comet assay. When cells are electrophoresed in neutral pH, the image looks like a comet with a distinct head composing intact DNA and a tail consisting of damaged DNA (27). The comet assay

conducted at neutral pH detects mainly DNA double strand breaks (DSBs). Comet assays were conducted to examine the role of endogenous cyclin D1 in the DDR. *Cyclin D1*$^{+/+}$ and *cyclin D1*$^{-/-}$ 3T3 cells were treated with 2 μM doxurubicin for 16 hrs. The percentage of cells with a comet tail was calculated (Fig. 1A). After doxorubicin treatment about 14.5% cells have a comet tail in *cyclin D1*$^{+/+}$ cells. But only 1.4% cells have a comet tail in *cyclin D1*$^{-/-}$ cells. These results suggest endogenous cyclin D1 increases the DDR. Histone H2AX phosphorylation on a serine residue at the carboxyl terminus (Ser139) (producing γH2AX) is a sensitive marker for DNA double-strand breaks (DSBs). Western blot analysis was conducted to detect γH2AX in *cyclin D1*$^{+/+}$ and *cyclin D1*$^{-/-}$ MEFs treated with doxorubicin for 16 hrs (Fig. 1B). After doxorubicin treatment γH2AX increased more in *cyclin D1*$^{+/+}$ cells than that in *cyclin D1*$^{-/-}$ cells. To further determine if endogenous cyclin D1 plays a role in DDR we used specific cyclin D1 siRNA to knock down endogenous cyclin D1 in HCT116 colon cancer cell line. Cyclin D1 siRNA reduced cyclin D1 levels, and reduced 5-fluorouracil (5-FU)-induced γH2AX phosphorylation. Rad51 levels were also reduced upon the reduction in cyclin D1 protein levels (Fig. 1C). Collectively these studies suggest that endogenous cyclin D1 contributes to the DDR.

Cyclin D1a induces the cellular DNA-damage response and double-stranded DNA breaks

To determine the specific requirement for cyclin D1a vs. cyclin D1b in the DDR we conducted *cyclin D1*$^{-/-}$ cells reconstitution overexpression analysis. *Cyclin D1*$^{-/-}$cells were transduced with a retroviral expression vector encoding either cyclin D1a or cyclin D1b to overexpress each isoform. Two types of analysis were conducted to assess the relative abundance of the D type cyclin in the reconstitution by Western blot analysis. As cellular transduction was high, the relative abundance of cyclin D1a and cyclin D1b was approximately 3- to 4-fold greater than endogenous cyclin D1 level (Supplement Fig. 1 A,B). At a single cell level the relative abundance of cyclin D1a and cyclin D1b was similar to the abundance of endogenous cyclin D1b (Supplement Fig. 1C,D). (The difference in relative abundance per cell vs. total abundance by Western blot is because endogenous cyclin D1a expression fluctuates during the cell cycle and is at low levels during early G_1 and late S and G_2M.) These cell populations were treated with doxorubicin (2 μM) to induce DNA damage. Cyclin D1a enhanced comet formation 4-fold compared with the control vector ($p<0.01$). In contrast, although cyclin D1b was expressed at similar levels to cyclin D1a (Supplement Fig. 1), comet activity was induced only about 80% (Fig. 2A). Cyclin D1a increased the DDR assessed by comet assay significantly more than cyclin D1b ($p<0.01$, Fig. 2A).

The DDR response is capable of inducing a cell cycle arrest at the G_1/S or G_2/M boundary. In order to determine whether the cyclin D1a mediated DDR was associated with cell-cycle arrest, PI staining and FACS analysis was conducted. Doxorubicin increased the proportion of cells in the G_2/M phase in *cyclin D1*$^{-/-}$ MEFs (Fig. 2B). Reintroduction of cyclin D1a into *cyclin D1*$^{-/-}$ MEFs increased the proportion of G_2/M cells from 27.7% to 49.2% and enhanced doxorubicin-mediated induction of G_2/M from36.7% to 64.3% (Fig. 2B). In contrast, cyclin D1b failed to change the basal or doxorubicin induced G_2/M phase (27.7% to 28.8%, 36.7% to 36.6%) (Fig. 2B).

Phosphorylation of H2AX (known as γH2AX) is the most studied chromatin modification induced by double strand breaks. DSB induction of γH2AX results in the formation of large foci that are important for the accumulation and retention of DSB repair factors. Assemblage of nuclear repair foci containing γH2AX was assessed in *cyclin D1*$^{-/-}$ MEFs transduced with each cyclin D1 isoform. Cyclin D1a enhanced the basal- (Fig. 3A) and radiation-induced γH2AX (Fig. 3B). Western blot analysis demonstrated cyclin D1a enhanced more doxorubicin-mediated γH2AX (Fig. 3C). Cyclin D1b also induced γH2AX however quantitatively the effect was significantly less (Fig. 3C, lanes 4 vs lane 6, γH2AX L.E., S.E.). Western blot analysis of

cyclin D1$^{-/-}$ transduced cells with an antibody directed to the FLAG epitope confirmed the expression of cyclin D1a and cyclin D1b in the *cyclin D1*$^{-/-}$ MEFs (Fig. 3B, 3C).

γH2AX has been reported to occur after DDR in all phase of the cell cycle (28) or at the site of replication fork breakage in the S phase of SV40 transformed Hela cells (29,30). Cyclin D1 has been shown to inhibit S phase entry in some studies (31) or promote S phase entry in other studies (32). The induction of DNA synthesis by cyclin D1 could potentially contribute to the DDR induction of replication forks. In the current studies S phase was increased from 12.2% to 14.3% (Fig. 2B). The kinetics of DDR induction was rapid (15 mins) and preceded the effect on DNA synthesis (>6 hr). Cyclin D1 induction of DNA synthesis requires the serum dependent association with Cdk (33). To examine whether the effect of cyclin D1a on the DDR could be further uncoupled from the effect on DNA synthesis we examined the effect of cyclin D1 on the DDR in the absence of serum. The *cyclin D1*$^{+/+}$ and *cyclin D1*$^{-/-}$ cells had reduced DNA synthesis in the absence of serum (Supplement Fig. 2A). Cyclin D1 significantly enhanced the DDR as assessed by γH2AX induction (Supplement Fig. 2B) in the absence of serum. *Cyclin D1*$^{-/-}$ cells showed no increase in DDR in the absence of serum. To further examine whether the effect of cyclin D1a to induce DNA synthesis can be uncoupled from its ability to induce the DDR we conducted FACS analysis (BrdU/PI) to assess S phase of Doxorubicin treated *cyclin D1*$^{-/-}$ 3T3 cells transduced with cyclin D1a or cyclin D1b (Supplement Fig. 3). Cyclin D1a enhanced the DDR induced by doxorubicin, but not enhance S phase entry. Three lines of evidence therefore suggest the induction of the DDR by cyclin D1a can be uncoupled from its induction of DNA synthesis. As cyclin D1 induced the DDR within 15 minutes (Fig. 3B), preceding DNA synthesis, cyclin D1 induces the DDR in the absence of serum (Supplement Fig. 2), and cyclin D1 induces the DDR of doxorubicin without increasing S phase (Supplement Fig. 3). These studies suggest ability of cyclin D1 to induce the DDR can be dissociated from its ability to induce DNA synthesis.

The Cyclin D1a splice form binds to p21^{CIP1} and regulates the induction of p21^{CIP1} abundance

p21^{CIP1} is an essential target of p53 which governs components of the genotoxic response (34). We had observed the abundance of p21^{CIP1} was increased by transduction of *cyclin D1*$^{-/-}$ cells with cyclin D1a (Fig. 3B, 3C). p21^{CIP1} abundance was induced one hour after radiation and this induction was enhanced upon expression of cyclin D1a vs cyclin D1b (Fig. 3B). Correspondingly, the abundance of p21^{CIP1} was reduced in MEFs, bone marrow macrophages (BMMs) and 3T3 cells lacking cyclin D1 (Fig. 4A). Cyclin D1b induced the basal level of p21^{CIP1} but did not enhance the DDR-induction of p21^{CIP1} compared with vector control (Fig. 3B, p21^{CIP1} L.E., lanes 4 vs 12).

The induction of p21^{CIP1} by cyclin D1 raised the possibility that p21^{CIP1} may contribute to activation of DSB repair. In order to determine the mechanism by which cyclin D1a enhanced the DDR, *p21*$^{CIP1-/-}$ MEFs were transduced with retroviral expression vectors encoding cyclin D1a or cyclin D1b and treated with doxorubicin. The expression of cyclin D1a and cyclin D1b was confirmed by Western blotting (Fig. 4B). Cyclin D1 antibody (clone DCS-6) was used to detect both the endogenous cyclin D1 and the transduced cyclin D1 isoforms. Cyclin D1a enhanced basal and doxorubicin-induced phosphorylation of γH2AX (Fig. 4B) and the expression of Rad51. The relative induction of γH2AX, and Rad51 expression was greater with cyclin D1a compared with cyclin D1b. The enhancement of doxorubicin-mediated γH2AX phosphorylation and Rad51 expression was abrogated in *p21*$^{CIP1-/-}$ cells (Fig. 4B).

The increased abundance of p21^{CIP1} in *cyclin D1*$^{+/+}$ vs. *cyclin D1*$^{-/-}$ cells raised the possibility that cyclin D1 may physically associate with p21^{CIP1} to regulate the abundance of p21^{CIP1}. To examine the interaction between cyclin D1 and p21^{CIP1}, immunoprecipitation (IP), western blotting, and mammalian two hybrid analysis were conducted (Fig. 4C). The amino terminal

FLAG epitope was used to immunoprecipitate equal amounts of cyclin D1a or cyclin D1b and sequential western blotting was conducted with an antibody to the $p21^{CIP1}$ protein (Fig. 4C). Cyclin D1a bound to $p21^{CIP1}$. The relative abundance of $p21^{CIP1}$ associated with cyclin D1b was reduced approximately 90% compared with cyclin D1a (Fig. 4C).

The $p21^{CIP1}$ cDNA was linked to the Gal4 DNA binding domain, and the interaction with cyclin D1 was assessed in the context of a cyclin D1-VP16 fusion expression plasmid. Cyclin D1a enhanced $p21^{CIP1}$-Gal4 activity ~9-fold (Fig. 4D, left). Point mutation of the CDK binding site of cyclin D1 reduced or abrogated interaction with the $p21^{CIP1}$-Gal4 hybrid (Fig. 4D, left). The alternate splice form of cyclin D1 (cyclin D1b) failed to interact significantly with the $p21^{CIP1}$-Gal4 hybrid (Fig. 4D, left). Reciprocal analysis was conducted in which the cyclin D1 cDNA was linked to GAL4 and the $p21^{CIP1}$ cDNA was linked to VP16 in order to assess interaction using a multimeric Gal4 DNA binding site linked to a luciferase reporter (Fig. 4D, right). Cyclin D1a and $p21^{CIP1}$ coexpression enhanced reporter activity 5-fold. This activity was reduced 80% using the cyclin D1b cDNA as bait in the 2 hybrid assay (Fig. 4D, right).

Cyclin D1 induces formation of repair factors to chromatin

To examine further the mechanism by which cyclin D1a induced the DDR we considered recent studies demonstrating that the stable association of DDR factors with chromatin can trigger and amplify the DDR signal via in an ATM and DNA-PK dependent manner (21). We had previously demonstrated that cyclin D1a was in the context of local chromatin in ChIP assays at DNA transcription factor binding sites (35,36). We examined the possibility that cyclin D1a tethered to chromatin may function in a similar manner as DDR factors to activate the DDR. DNA repair factors fused to the *Escherichia coli* lac-repressor (lacR) and tagged with Cherry-red fluorescent protein were examined in an NIH3T3 cell line that contains 256 repeats of the lac operator sequence (lacO) stably integrated into chromosome 3, known as NIH2/4 (25). Fusion proteins accumulated at the lacO array as distinct nuclear foci: immobilization of ATM, NBS1 or MDC1 was sufficient to activate the DDR as evidenced by phosphorylation of γH2AX at the lacO site (Fig. 5A–C). Phosphorylation of γH2AX at the lacO site was enhanced by NBS1, MDC1 or ATM alone as previously shown (21). Immobilization of cyclin D1b did not affect γH2AX phosphorylation. Immobilization of cyclin D1a in chromatin however enhanced γH2AX phosphorylation substantially (Fig. 5B, 5C). Thus, immobilization of cyclin D1a in the context of local chromatin is sufficient to activate the DDR.

In the absence of DNA damage neither cyclin D1a nor cyclin D1b can recruit Rad51 to local chromatin (Supplement Fig.4). Rad51 is involved in recombination repair of double-strand breaks. Additional experiments were conducted to address if both cyclin D1 isoforms could recruit Rad51 to local chromatin in response to DNA damage. NIH2/4 cells were transfected with Cherry-lacR-NLS-cyclin D1a, Cherry-lacR-NLS-cyclin D1b, or vector control Cherry-lacR-NLS. 24 hours later cells were treated with 0.4 μM doxorubicin for 3 hours. Then immunofluorescence staining was conducted using specific antibody to Rad51. We found that only cyclin D1a recruits Rad51 to local chromatin in response to DNA damage (Fig. 5D).

Cyclin D1a enhancement of doxorubicin-induced γH2AX involves DNA-PK, JNK, and casein kinase 2 (CK2)

The current studies demonstrated that cyclin D1a increases γH2AX phosphorylation induced by γ irradiation or chemotherapy agents (doxorubicin or 5-FU) in fibroblasts or in a colon cancer cells line HCT116 cells (Fig. 1, Fig. 3). To examine further the mechanism by which cyclin D1 induced γH2AX, we treated 3T3 cells with doxorubicin combined with inhibitors of the DDR signaling pathway. Western blot analysis was conducted to detect γH2AX. Compared to vehicle control, the DNA-PK inhibitor (NU7026), CK2 inhibitor (TBB), and JNK inhibitor (SP600125) reduced doxorubicin-induced γH2AX in cyclin D1a transduced cells

(Supplement Fig. 4B, $p<0.05$), but not in control vector tranduced cells (supplement Fig. 4C). In contrast the ATM inhibitor (KU55933) didn't show a significant change. These findings suggest cyclin D1a induction of doxorubicin-induced γH2AX involves DNA-PK, JNK and CK2 (Supplement Fig. 4C).

DISCUSSION

Cyclin D1a enhances the DDR

The current studies provide evidence for an important new function of cyclin D1a overexpression in amplifying the cellular DNA-damage response. Induction of the DDR by cyclin D1a was evidenced by enhanced formation of damaged double-stranded DNA assessed by Comet assay activity, induction of Rad51 foci, formation and induction of γH2AX phosphorylation. Cyclin D1-mediated DDR was observed with the cyclin D1a vs the cyclin D1b isoform. The physiological relevance of the amplification of DDR by cyclin D1a was evidenced by the findings that siRNA to endogenous cyclin D1 reduced the DDR phenotype. The importance of cyclin D1a in the DDR was demonstrated using distinct activators of the DDR, including γ irradiation, double stranded-DNA damage inducing agents (doxorubicin, 5-FU) and the targeting of single DNA repair factors to chromatin.

The prior studies of cyclin D1 in regulating the DDR suggest cell-type dependent functions. Forced expression of cyclin E, but not cyclin D1, in rat embryo fibroblasts induces aneuploidy but did not affect gene amplification (37). Forced expression of a degradation defective mutant of cyclin E induced more aneuploidy (37). In subsequent studies, genome wide microarray analysis demonstrated cyclin D1 induced expression of genes involved in DNA replication and DNA damage checkpoints suggesting a role for cyclin D1 in the DDR. Cyclin D1a induced the mRNA expression of Minichromosome maintenance (MCM)3, MCM4, replication factor C (activator 1) 4 (Rfc4), cell division cycle 6 homology (Cdc6), cell division cell associated 7 (Cdc7) and H2Afx (H2A Histone family member X) in MEFs (38). Mammary gland targeted cyclin D1 inducible antisense transgenics demonstrated endogenous cyclin D1 maintained expression of MCM2, Rfc2, Cdc20, Rad51 and histone 1 in the mammary epithelium (39). In subsequent studies forced expression of cyclin D1 induced expression of genes regulating the DDR, as MCM3 and Cdc7 (40) expression were increased in mammary tumors derived from mammary epithelial cell targeted cyclin D1a transgenic mice. Forced expression of a degradation defective cyclin D1a mutant induced the DDR in murine lymphoid tissue (41). Thus prior indirect evidence implicated cyclin D1 in enhancing gene expression governing the DDR in a number of different cell types.

Cyclin D1 induction of the DDR requires $p21^{CIP1}$

Herein cyclin D1 bound to, and augmented the abundance of, $p21^{CIP1}$. In $p21^{CIP1-/-}$ MEFs, cyclin D1 expression failed to increase doxorubicin-induced γH2AX (Figure 5B). This suggests cyclin D1 may increase DDR through $p21^{CIP1}$. Prior studies demonstrated that downregulation of $p21^{CIP1}$ inhibited Rad51 foci formation (42). Expression of Rad51, which is involved in the repair of DSBs induced by cisplatin and other platinum agents (43, 44) was induced by cyclin D1a. Elevated Rad51 levels are found in tumor cell lines and primary tumors (34), and correlated with resistance to drug and radiation therapy, tumor recurrence (45) and poor prognosis (46–48). The function of a number of tumor suppressor genes have been linked to elevated Rad51 levels, suggesting increased Rad51 activity may promote tumorigenesis (34, 45).

Cyclin D1a recruitment to local chromatin elicits the DDR

The current studies demonstrated that the recruitment of cyclin D1a, but not cyclin D1b, is sufficient to activate the DDR. The recruitment of DNA repair factors to chromatin is also

sufficient to elicit the DDR characterized by γH2AX phosphorylation. In prior studies, cyclin D1a reintroduction into *cyclin D1*$^{-/-}$ cells resulted in recruitment of cyclin D1 to chromatin at a PPARE, associated with local deacetylation of core histones, in particular of H3Lys9 (35). Cyclin D1a recruits SUV39 and HP1α (38) to local chromatin and HP1β mobilization is thought to promote chromatin changes that initiate the DDR (49). The recruitment of DNA repair factors to chromatin induces a G_2/M delay (25). In prior studies DNA-damaging agents, and as shown here, cyclin D1a, induced a G_2/M arrest. As cyclin D1a enhanced recruitment of DNA repair factors to chromatin this effect may contribute to the G_2/M arrest.

Cyclin D1 is expressed early in a variety of human cancers and premalignant disease including colonic polyps and breast ductal carcinoma *in situ*. Activation of the DDR occurs in human cancer (50). The current studies suggest cyclin D1a may contribute to the induction of DDR in tumors. The induction of DDR occurred more with cyclin D1a than cyclin D1b. Clinical studies will be important to determine the role of cyclin D1 isoforms in therapeutic stratification of patients receiving therapy inducing the DDR.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful to Drs. Dennis Leeper and Phyllis Wachsberger for helping in γ irradiation cells. We thank Atenssa L. Cheek for the preparation of this manuscript.

Grant Support

This work was supported in part by R01CA70896, R01CA75503, R01CA107382, R01CA86072, R01CA132115 (R.G.P.) and the Kimmel Cancer Center is supported by the NIH Cancer Center Core grant P30CA56036 (R.G.P.). This project is a generous grant from the Dr. Ralph and Marian C. Falk Medical Research Trust funded and supported in part by a grant from the Pennsylvania Department of Health. The Department disclaims responsibility for any analysis, interpretations or conclusions.

References

1. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499–506. [PubMed: 12556884]
2. Bekker-Jensen S, Lukas C, Kitagawa R, Melander F, Kastan MB, Bartek J, et al. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. Journal of Cell Biology 2006;173:195–206. [PubMed: 16618811]
3. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003;3:421–9. [PubMed: 12781359]
4. Lowndes NF, Toh GW. DNA repair: the importance of phosphorylating histone H2AX. Curr Biol 2005;15:R99–R102. [PubMed: 15694301]
5. Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008;2:296–316. [PubMed: 19383352]
6. Denko NC, Giaccia AJ, Stringer JR, Stambrook PJ. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci U S A 1994;91:5124–8. [PubMed: 8197195]
7. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006;444:633–7. [PubMed: 17136093]
8. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006;444:638–42. [PubMed: 17136094]

9. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864–70. [PubMed: 15829956]
10. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907–13. [PubMed: 15829965]
11. Sherr CJ, Roberts JM. CDK inhibitors:positive and negative regulators of G1-phase progression. Genes and Dev 1999;13:1501–12. [PubMed: 10385618]
12. Agami R, Bernards R. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 2000;102:55–66. [PubMed: 10929713]
13. Albanese C, D'Amico M, Reutens AT, Fu M, Watanabe G, Lee RJ, et al. Activation of the *cyclin D1* gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 1999;274:34186–95. [PubMed: 10567390]
14. Coco Martin JM, Balkenende A, Verschoor T, Lallemand F, Michalides R. Cyclin D1 overexpression enhances radiation-induced apoptosis and radiosensitivity in a breast tumor cell line. Cancer Res 1999;59:1134–40. [PubMed: 10070974]
15. Zhou Q, Fukushima P, DeGraff W, Mitchell JB, Stetler Stevenson M, Ashkenazi A, et al. Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1. Cancer Res 2000;60:2611–5. [PubMed: 10825131]
16. Sherr CJ. D1 in G2. Cell Cycle 2002;1:36–8. [PubMed: 12429906]
17. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: Normal and Abnormal Functions. Endocrinology 2004;145:5439–47. [PubMed: 15331580]
18. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006;25:1620–8. [PubMed: 16550162]
19. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000;60:249–52. [PubMed: 10667569]
20. Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 2003;278:30339–47. [PubMed: 12746453]
21. Soutoglou E, Misteli T. Activation of the cellular DNA damage response in the absence of DNA lesions. Science 2008;320:1507–10. [PubMed: 18483401]
22. Li Z, Wang C, Jiao X, Katiyar S, Casimiro MC, Prendergast GC, et al. Alternate Cyclin D1 mRNA Splicing Modulates p27KIP1 Binding and Cell Migration. J Biol Chem 2008;283:7007–15. [PubMed: 18180298]
23. Li Z, Jiao X, Wang C, Ju X, Lu Y, Yuan L, et al. Cyclin D1 induction of cellular migration requires p27(KIP1). Cancer Res 2006;66:9986–94. [PubMed: 17047061]
24. Li Z, Wang C, Jiao X, Lu Y, Fu M, Quong AA, et al. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol 2006;26:4240–56. [PubMed: 16705174]
25. Soutoglou E, Dorn JF, Sengupta K, Jasin M, Nussenzweig A, Ried T, et al. Positional stability of single double-strand breaks in mammalian cells. Nat Cell Biol 2007;9:675–82. [PubMed: 17486118]
26. Tsai WB, Chung YM, Takahashi Y, Xu Z, Hu MC. Functional interaction between FOXO3a and ATM regulates DNA damage response. Nat Cell Biol 2008;10:460–7. [PubMed: 18344987]
27. Piperakis SM. Comet assay: a brief history. Cell Biol Toxicol 2009;25:1–3. [PubMed: 18553144]
28. Halicka HD, Huang X, Traganos F, King MA, Dai W, Darzynkiewicz Z. Histone H2AX phosphorylation after cell irradiation with UV-B: relationship to cell cycle phase and induction of apoptosis. Cell Cycle 2005;4:339–45. [PubMed: 15655354]
29. Limoli CL, Giedzinski E, Bonner WM, Cleaver JE. UV-induced replication arrest in the xeroderma pigmentosum variant leads to DNA double-strand breaks, gamma -H2AX formation, and Mre11 relocalization. Proc Natl Acad Sci U S A 2002;99:233–8. [PubMed: 11756691]
30. Limoli CL, Laposa R, Cleaver JE. DNA replication arrest in XP variant cells after UV exposure is diverted into an Mre11-dependent recombination pathway by the kinase inhibitor wortmannin. Mutat Res 2002;510:121–9. [PubMed: 12459448]

31. Pagano M, Theodoras AM, Tam SW, Draetta GF. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 1994;8:1627–39. [PubMed: 7958844]
32. Wang C, Fu M, D'Amico M, Albanese C, Zhou JN, Brownlee M, et al. Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol 2001;21:3057–70. [PubMed: 11287611]
33. Kato, J-y; Matsuoka, M.; Stromm, DK.; Sherr, CJ. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol Cell Biol 1994;14:2713–21. [PubMed: 8139570]
34. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 2002;62:219–25. [PubMed: 11782381]
35. Fu M, Rao M, Bouras T, Wang C, Wu K, Zhang X, et al. Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. J Biol Chem 2005;280:16934–41. [PubMed: 15713663]
36. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol 2003;23:6159–73. [PubMed: 12917338]
37. Spruck C, Won K, Reed S. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297–300. [PubMed: 10499591]
38. Fu M, Rao M, Bouras T, Wang C, Wu K, Zhang X, et al. Cyclin D1 inhibits PPARgamma -mediated adipogenesis through HDAC recruitment. J Biol Chem 2005;280:16934–41. [PubMed: 15713663]
39. Sakamaki T, Casimiro MC, Ju X, Quong AA, Katiyar S, Liu M, et al. Cyclin D1 determines mitochondrial function in vivo. Mol Cell Biol 2006;26:5449–69. [PubMed: 16809779]
40. Lin DI, Lessie MD, Gladden AB, Bassing CH, Wagner KU, Diehl JA. Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene 2008;27:1231–42. [PubMed: 17724472]
41. Aggarwal P, Lessie MD, Lin DI, Pontano L, Gladden AB, Nuskey B, et al. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev 2007;21:2908–22. [PubMed: 18006686]
42. Raderschall E, Bazarov A, Cao J, Lurz R, Smith A, Mann W, et al. Formation of higher-order nuclear Rad51 structures is functionally linked to p21 expression and protection from DNA damage-induced apoptosis. J Cell Sci 2002;115:153–64. [PubMed: 11801733]
43. Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, Yoshimura M, et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 2005;65:11704–11. [PubMed: 16357182]
44. van Waardenburg RC, de Jong LA, van Eijndhoven MA, Verseyden C, Pluim D, Jansen LE, et al. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. J Biol Chem 2004;279:54502–9. [PubMed: 15471886]
45. Henning W, Sturzbecher HW. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 2003;193:91–109. [PubMed: 14599770]
46. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol 2006;28:1113–9. [PubMed: 16596227]
47. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002;62:2890–6. [PubMed: 12019169]
48. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S, et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 2000;88:907–13. [PubMed: 11093813]
49. Ayoub N, Jeyasekharan AD, Bernal JA, Venkitaraman AR. HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response. Nature 2008;453:682–6. [PubMed: 18438399]
50. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008;319:1352–5. [PubMed: 18323444]



Figure 1. Endogenous cyclin D1 increases the DNA damage response (DDR)

(A) The comet assay was conducted as a single cell DNA damage assay at neutral pH. Neutral pH comet assay detects mainly DNA double strand breaks (DSBs). *Cyclin D1*$^{+/+}$ and *cyclin D1*$^{-/-}$ 3T3 cells were treated with 2 μM doxurubicin for 16 hrs. Scale bar, 100μm. The percentage of cells with comet tail was showed in the right panel. (B) Western blot analysis of *cyclin D*$^{+/+}$ and *cyclin D1*$^{-/-}$ MEFs treated with doxorubicin for 16 hrs. Antibodies are directed to γH2AX (Ser139), Rad51. Vinculin expression was used as a protein loading control. S.E. stands for shorter exposure. L.E. stands for longer exposure. (C) Knocking down endogenous cyclin D1 decreases 5-FU induced γH2AX in HCT116 colon cancer cell line. Western blot analysis of the HCT116 colon cancer cell line transfected with control or cyclin D1 siRNA prior to treatment with 5-FU for 24 hrs.



Figure 2. Alternate cyclin D1 splice forms differentially regulate the DNA damage response and a G_2 delay

(A) Neutral pH comet assay was conducted as a single cell DNA damage assay. The tail of the DNA comet reflects the amount of damaged DNA and was quantified using TriTek Comet Score software. Data are mean ± SEM of N=100 cells per condition. *Cyclin D1*$^{-/-}$ MEFs were transduced with retroviral expression vectors encoding either the cyclin D1a or cyclin D1b splice forms, and treated with 2 μM doxurubicin for 16 hrs. Scale bar, 100 μm. (B) Fluorescence activated cell sorting of *cyclin D1*$^{-/-}$ cells rescued with cyclin D1a or cyclin D1b viral expression vectors. Cells were treated with 0.5 μM Doxurubicin for 24 hrs prior to being stained with propidium iodide and cell cycle analysis by FACS.



Figure 3. Induction of γH2AX foci by cyclin D1a isoform

(A) Confocal microscopy for γH2AX with nuclear staining using DAPI. *Cyclin D1*$^{-/-}$ MEFs were transduced with cyclin D1 expression vectors as indicated. Scale bar, 10 μm. (B, C) Western blot analysis of *cyclin D1*$^{-/-}$ cells transduced with cyclin D1 isoform specific retrovirus as indicated. Antibodies are directed to γH2AX (Ser139). Cells were treated with 40Gy irradiation (B) or Doxorubicin (C). S.E. stands for shorter exposure. L.E. stands for longer exposure.



Figure 4. Cyclin D1a-mediated cellular DNA damage response involves p21^{CIP1}

(A) Western blot analysis of *cyclin D1*$^{+/+}$ and *cyclin D1*$^{-/-}$ cells indicates reduction in p21^{CIP1} abundance in *cyclin D1*$^{-/-}$ cells. (B) *p21*$^{CIP1-/-}$ cells transduced with isoform specific cyclin D1 retrovirus vectors and treated with the DDR inducing agent Doxorubicin. Cyclin D1 antibody (clone DCS-6) was used to detect both the endogenous and the transduced cyclin D1 isoforms. The induction of γH2AX (Ser139) by cyclin D1a is attenuated in *p21*$^{CIP1-/-}$ cells. (C) Immunoprecipitation-Western blot analysis of cyclin D1 isoforms indicates co-association of cyclin D1 with endogenous p21^{CIP1} and Rad51. (D) Mammalian two-hybrid demonstrates preferential co-association of p21^{CIP1} with cyclin D1a. Data are mean ± SEM luciferase activity.



Figure 5. (A–C) Immobilization of single DNA repair factors, or the cyclin D1a splice form, on chromatin leads to DDR activation

(A) Schematic representation of the chimeric fusion proteins in which the DNA repair factors, or the cyclin D1 isoforms, were linked to Cherry-lacR-NLS. (B) Confocal immunofluorescence microscopy of NIH 2/4 cells transiently transfected with cyclin D1 isoforms or repair factor fused to Cherry-lacR-NLS (red). Phosphorylation of γH2AX (green) indicates DDR activation. (C) γH2AX phosphorylation on the lacO array was quantitated for > 40 cells and was normalized with the cherry-lacR-NLS vector control for a representative example from 3 separate experiments. **(D) Cyclin D1a isoform recruits Rad51 to local chromatin in response to DNA damage.** NIH2/4 cells were transfected with Cherry-lacR-NLS-cyclin D1a, Cherry-lacR-NLS-cyclin D1b, or vector control Cherry-lacR-NLS by using Nuclofector system. 24 hours later cells were treated with 0.4 μM doxorubicin for 3 hours. Then immunofluorescence staining was conducted using specific antibody to Rad51 (clone H-92). The lower part showing a model of Cherry-lacR/lacO system and cyclin D1a inducing γH2AX foci in the absence of DNA damage, cyclin D1a recruiting Rad51 to local chromatin in response to DNA damage, and cyclin D1b failing to recruit Rad51 even in the response to DNA damage.